🔥Off the press: ASCO #LivingGuidelines for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1 | 👉🏽 ascopubs.org/doi/10.1200/JC… ✅ Clear algorithm for first and second line options ✅ Review of recent data:

🔥BREAKING🆙 Positive OS‼️ ✅FLAURA2: Osimertinib + Chemo vs Osimertinib 🎯"Statistically significant and clinically meaningful improvement in the key secondary endpoint of OS" 🗣️AstraZeneca OncoAlert LARVOL #EGFR EGFR Resisters astrazeneca.com/media-centre/p…

Viewpoint: The rise of social media and #AI in oncology has transformed scientific communication but also fuels bias, misinterpretation, and financial conflicts of interest. ja.ma/3UrqGLH Raffaele Giusti

Understanding and overcoming multidrug resistance in cancer A great review on drug resistance, one of the strongest weapons of our opponent in our fight against cancer👇 nature.com/articles/s4157…

🚨 FDA grants accelerated approval to zongertinib for previously treated patients with HER2-mutated NSCLC, based on Phase 1b BEAMION-LUNG 1: ✅ RR 71% (42% post-ADC) ✅ DOR 14.1 mo ✅ Intracranial RR 41% ⚠️ Main AE: diarrhea, no ILD Great news for patients — this is the first

Most viewed this week from JAMA Oncology: A deep learning #AI model showed improved accuracy over existing biomarkers in predicting immune checkpoint inhibitor treatment response in advanced non-small cell lung #cancer patients. ja.ma/45oYEFD

Mayo Clinic retrospective analysis: Induction chemo+ IO → cCRT → +/- maintenance ICI appears feasible in stage III NSCLC patients not suitable for upfront cCRT (n:29) ORR➡️ 93% (induction phase) mPFS➡️18 mo mOS➡️24 mo ❗️Adverse events: pneumonitis 37.9% (≥grade 3: 18%),

🫁 Advances in lung cancer research 2025 (NSCLC). From genomics, tumor heterogeneity, and metabolic reprogramming to immunobiology and the microbiome, basic & translational science is shaping future curative strategies. 📖 JTO & JTO CRR DOI 👉🏻 doi.org/10.1016/j.jtho… #CánCare

🚨 Rare thoracic tumors The Lancet Jordi Remon et al. Pembro+ lenvatinib shows promising activity in pretreated metastatic B3 thymoma & thymic carcinoma. ◼️ ORR exceeds monotherapy results ◼️ Median PFS improved ◼️ Toxicity manageable A potential new standard? LungCancerRx 🫁💊

🫁 Lung metastases in clinical practice. Affecting up to 50% of patients with metastatic cancer, lung metastases worsen prognosis and QoL. Current care relies on histology- and molecular-driven systemic therapy, with no specific standard available. 📖 Nature Reviews Disease Primers DOI 👉

🔥🚨OncoAlert HOT OFF THE PRESS. Just presented at the presidential symposium IASLC #WCLC25 The long awaited #OverallSurvival data from: ⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osimertinib in 1st line Tx for patients with #EGFR+ advanced #LungCancer (#NSCLC).

Check out our investigation into what clinical and pathologic factors are associated with proceeding to surgery and with pCR in the real world - we need a better understanding of patient selection to determine who most likely to benefit.

Best slides of #WCLC25 ? Jordi Remon’s thoughtful discussion of ACROSS-2, a prospective trial incorporating treatment selection based on tumour suppressor genes. Great summary of key subgroups of EGFR+ NSCLC, & combo tx outcomes IASLC EGFR Resisters OncoAlert #LCSM

Viewpoint: Recognizing the heterogeneity of small cell lung cancer, efforts are underway to apply precision oncology through molecular subtyping and targeted therapies for tailored treatment. ja.ma/4miuryo

🚨 Excited to share our 2 new studies published today in The Lancet Oncology — one offering deeper insight into refining #ICI for PD-L1–negative & 🧬#STK11-mutant #NSCLC, and the other exploring #ICI vs 💊#BRAF/MEKi in #BRAF V600E #NSCLC. OncoAlert IASLC #LCSM. /W✨Alessandro Di Federico✨

IO + Lurbinectedin as maintenance is now U.S. FDA approved after 4 cycles of Chemo + IO for ES-SCLC based off #IMForte study: - mOS 13.2 vs 10.6mos (HR: 0.73) - mPFS 5.4 vs 2.1mos (HR: 0.54) - Higher Gr3/4 AEs with Lurbi + Atezo #OncTwitter #MedTwitter #lcsm

🫁 Nat Rev Clin Oncol: review on unresectable stage III NSCLC…still a tough battlefield! nature.com/articles/s4157… 🌊 PACIFIC = SOC (CRT→durvalumab) for EGFR/ALK WT 👩🏼 LAURA = osimertinib consolidation for EGFR+ → unprecedented PFS 🎯 ctDNA monitoring, novel RT & chemo-IO

FLAURA - 2 Exploratory OS analysis in patients with poorer prognostic factors. Osimertinib plus chemotherapy improves outcomes in these subgroups. ( some results did not reach statistical significance) ESMO - Eur. Oncology #ESMO25 #NSCLC #lcsm

Review in JAMA on lung cancer in patients with no smoking history, who now make up about 20% of all new cases of lung cancer. The biology of these cancers is different, as is the treatment, but the gravity is the same. Read now at JAMA. jamanetwork.com/journals/jama/…